The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June.
There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...
Hosted on MSN2mon
Merck eyeing 2025 launch for easier-to-use KeytrudaMerck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...
Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in 2028, Jared Hopkins of The Wall Street Journal reports.
For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...
6mon
Investor's Business Daily on MSNMerck Dives After Summit — Up 56% — Sneaks In With Keytruda-Walloping PunchMerck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...
The firm believes the “real culprit” for Merck shares remaining under pressure is Keytruda’s 2028 patent expiration. Despite the company building out its pipeline, past precedence shows the ...
The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results